A Comprehensive Review of Novel FDA-Approved Psychiatric Medications (2018-2022).

Cureus · 2024 · PMC11028406 · PMID 38646400

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The results showed a trend for a dose-related improvement in symptoms of depression as determined by the mean reduction of 11.2 points in the MADRS total score for patients in the lumateperone group, while patients in the placebo group had a mean reduction of 6.6 points [ 41 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.